Business
ALNOV: FY 2024 revenue up 85% to £19.6m, with strong Reproductive Health and cost efficiencies
ALNOV: FY 2024 revenue up 85% to £19.6m, with strong Reproductive Health and cost efficiencies
About this update from Novacyt Sas
Novacyt expects FY 2024 revenue to nearly double to £19.6m, driven by the Yourgene acquisition and strong Reproductive Health growth. Operational consolidation and new product launches position the group for long-term expansion. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.